More from BMY Q2 2026

1mo

Growth portfolio transition: Qvantig, Opdualag, Reblozyl, Breyanzi strength

Growth portfolio revenue rose 14% to $7.6B in Q2 and represented nearly 60% of total revenue.
Qvantig delivered $261M revenue in Q2 and is now annualizing at over $1B, driven by ongoing U.S. conversion from Opdivo.
Opdualag delivered another quarter of strong double-digit growth, positioned as a standard of care in first-line melanoma in the U.S.
Reblozyl grew 29% on uptake in first-line MDS-associated anemia and penetration in first-line RS-negative population.
Breyanzi grew 41%, supported by strong demand across approved indications in both U.S. and international markets.

1mo

Financial Performance Summary

Balance sheet/cash: $11.5B cash equivalents and marketable securities (as of June 30); operating cash flow of ~$3.4B; debt paydown of $1.2B.
Cardiovascular/immunology results included Eliquis revenue of ~$4.5B (+21%), Camzyos $416M (+59%), and Sotyktu +23%.
Growth portfolio revenue rose 14% to $7.6B and represented nearly 60% of total revenue.
Hematology growth included Reblozyl +29% and Breyanzi +41% driven by demand across approved indications in the U.S. and internationally.
In oncology, Qvantig revenue was $261M and annualizing at over $1B; Opdivo declined 4% to ~$2.5B mainly from conversion to Qvantig in the U.S.
Neuroscience: Cobenfy revenue grew 81% to $63M in Q2.
Q2 2026 total revenue increased 5% year-over-year to approximately $13.0B, with growth portfolio strength offsetting legacy portfolio decline.
Q2 gross margin was 71.4% (product mix); operating expenses were $4.1B; diluted EPS was $2.04; effective tax rate was 16.5%.

1mo

10 products with double-digit growth

Growth portfolio accelerated: 10 products achieved double-digit growth

Management highlighted that across the overall portfolio, 10 products delivered double-digit growth within the growth portfolio transition narrative.

More from BMY Q2 2026

1mo

Growth portfolio transition: Qvantig, Opdualag, Reblozyl, Breyanzi strength

Growth portfolio revenue rose 14% to $7.6B in Q2 and represented nearly 60% of total revenue.
Qvantig delivered $261M revenue in Q2 and is now annualizing at over $1B, driven by ongoing U.S. conversion from Opdivo.
Opdualag delivered another quarter of strong double-digit growth, positioned as a standard of care in first-line melanoma in the U.S.
Reblozyl grew 29% on uptake in first-line MDS-associated anemia and penetration in first-line RS-negative population.
Breyanzi grew 41%, supported by strong demand across approved indications in both U.S. and international markets.

1mo

Financial Performance Summary

Balance sheet/cash: $11.5B cash equivalents and marketable securities (as of June 30); operating cash flow of ~$3.4B; debt paydown of $1.2B.
Cardiovascular/immunology results included Eliquis revenue of ~$4.5B (+21%), Camzyos $416M (+59%), and Sotyktu +23%.
Growth portfolio revenue rose 14% to $7.6B and represented nearly 60% of total revenue.
Hematology growth included Reblozyl +29% and Breyanzi +41% driven by demand across approved indications in the U.S. and internationally.
In oncology, Qvantig revenue was $261M and annualizing at over $1B; Opdivo declined 4% to ~$2.5B mainly from conversion to Qvantig in the U.S.
Neuroscience: Cobenfy revenue grew 81% to $63M in Q2.
Q2 2026 total revenue increased 5% year-over-year to approximately $13.0B, with growth portfolio strength offsetting legacy portfolio decline.
Q2 gross margin was 71.4% (product mix); operating expenses were $4.1B; diluted EPS was $2.04; effective tax rate was 16.5%.

1mo

10 products with double-digit growth

Growth portfolio accelerated: 10 products achieved double-digit growth

Management highlighted that across the overall portfolio, 10 products delivered double-digit growth within the growth portfolio transition narrative.

Bristol-Myers Squibb Company Earnings Quote from David Elkins

More from BMY Q2 2026